These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 22683823)

  • 1. Review of cytomegalovirus infection findings with mammalian target of rapamycin inhibitor-based immunosuppressive therapy in de novo renal transplant recipients.
    Nashan B; Gaston R; Emery V; Säemann MD; Mueller NJ; Couzi L; Dantal J; Shihab F; Mulgaonkar S; Seun Kim Y; Brennan DC
    Transplantation; 2012 Jun; 93(11):1075-85. PubMed ID: 22683823
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Everolimus is associated with a reduced incidence of cytomegalovirus infection following de novo cardiac transplantation.
    Kobashigawa J; Ross H; Bara C; Delgado JF; Dengler T; Lehmkuhl HB; Wang SS; Dong G; Witte S; Junge G; Potena L
    Transpl Infect Dis; 2013 Apr; 15(2):150-62. PubMed ID: 23013440
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A lower incidence of cytomegalovirus infection in de novo heart transplant recipients randomized to everolimus.
    Hill JA; Hummel M; Starling RC; Kobashigawa JA; Perrone SV; Arizón JM; Simonsen S; Abeywickrama KH; Bara C
    Transplantation; 2007 Dec; 84(11):1436-42. PubMed ID: 18091519
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduced risk of cytomegalovirus infection in solid organ transplant recipients treated with sirolimus: a pooled analysis of clinical trials.
    Demopoulos L; Polinsky M; Steele G; Mines D; Blum M; Caulfield M; Adamkovic A; Liu Q; Harler MB; Hahn C; Singh A
    Transplant Proc; 2008 Jun; 40(5):1407-10. PubMed ID: 18589118
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Wound healing complications and the use of mammalian target of rapamycin inhibitors in kidney transplantation: a critical review of the literature.
    Nashan B; Citterio F
    Transplantation; 2012 Sep; 94(6):547-61. PubMed ID: 22941182
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical evidence on the use of anti-mTOR drugs in renal transplantation.
    Hernández D; Martínez D; Gutiérrez E; López V; Gutiérrez C; García P; Cobelo C; Cabello M; Burgos D; Sola E; González-Molina M
    Nefrologia; 2011; 31(1):27-34. PubMed ID: 21270910
    [TBL] [Abstract][Full Text] [Related]  

  • 7. From clinical trials to clinical practice: an overview of Certican (everolimus) in heart transplantation.
    Valantine H; Zuckermann A
    J Heart Lung Transplant; 2005 Apr; 24(4 Suppl):S185-90; discussion S210-1. PubMed ID: 15774320
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Everolimus in clinical practice--renal transplantation.
    Pascual J
    Nephrol Dial Transplant; 2006 Jul; 21 Suppl 3():iii18-23. PubMed ID: 16815852
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Everolimus-based immunosuppressive regimens in lung transplant recipients: impact on CMV infection.
    Rittà M; Costa C; Solidoro P; Sidoti F; Libertucci D; Boffini M; Rinaldi M; Baldi S; Cavallo R
    Antiviral Res; 2015 Jan; 113():19-26. PubMed ID: 25446337
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Decreased incidence of cytomegalovirus infection with sirolimus in a post hoc randomized, multicenter study in lung transplantation.
    Ghassemieh B; Ahya VN; Baz MA; Valentine VG; Arcasoy SM; Love RB; Seethamraju H; Alex CG; Bag R; DeOliveira NC; Vigneswaran WT; Charbeneau J; Garrity ER; Bhorade SM
    J Heart Lung Transplant; 2013 Jul; 32(7):701-6. PubMed ID: 23664526
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sirolimus exposure during the early post-transplant period reduces the risk of CMV infection relative to tacrolimus in renal allograft recipients.
    Haririan A; Morawski K; West MS; El-Amm JM; Doshi MD; Cincotta E; Alangaden GJ; Chandrasekar P; Gruber SA
    Clin Transplant; 2007; 21(4):466-71. PubMed ID: 17645705
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of sirolimus-based immunosuppression vs. conventional prophylaxis therapy on cytomegalovirus infection after liver transplantation.
    Sheng L; Jun S; Jianfeng L; Lianghui G
    Clin Transplant; 2015 Jun; 29(6):555-9. PubMed ID: 25851741
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Everolimus: preventing organ rejection in adult kidney transplant recipients.
    Dantal J
    Expert Opin Pharmacother; 2012 Apr; 13(5):767-78. PubMed ID: 22404500
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Everolimus-treated renal transplant recipients have a more robust CMV-specific CD8+ T-cell response compared with cyclosporine- or mycophenolate-treated patients.
    Havenith SH; Yong SL; van Donselaar-van der Pant KA; van Lier RA; ten Berge IJ; Bemelman FJ
    Transplantation; 2013 Jan; 95(1):184-91. PubMed ID: 23222818
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potential role of proliferation signal inhibitors on atherosclerosis in renal transplant patients.
    Andrés V; Castro C; Campistol JM
    Nephrol Dial Transplant; 2006 Jul; 21 Suppl 3():iii14-7. PubMed ID: 16815851
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recommendations for use of everolimus after heart transplantation: results from a Latin-American Consensus Meeting.
    Bocchi EA; Ahualli L; Amuchastegui M; Boullon F; Cerutti B; Colque R; Fernandez D; Fiorelli A; Olaya P; Vulcado N; Perrone SV
    Transplant Proc; 2006 Apr; 38(3):937-42. PubMed ID: 16647515
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Everolimus immunosuppression in de novo heart transplant recipients: what does the evidence tell us now?
    Zuckermann A; Wang SS; Epailly E; Barten MJ; Sigurdardottir V; Segovia J; Varnous S; Turazza FM; Potena L; Lehmkuhl HB
    Transplant Rev (Orlando); 2013 Jul; 27(3):76-84. PubMed ID: 23643624
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Decreased Cytomegalovirus infection after antilymphocyte therapy in sirolimus-treated renal transplant patients.
    Ozaki KS; Câmara NO; Galante NZ; Camargo LF; Pacheco-Silva A
    Int Immunopharmacol; 2005 Jan; 5(1):103-6. PubMed ID: 15589467
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination of everolimus with calcineurin inhibitor medication resulted in post-transplant haemolytic uraemic syndrome in lung transplant recipients--a case series.
    Lovric S; Kielstein JT; Kayser D; Bröcker V; Becker JU; Hiss M; Schiffer M; Sommerwerck U; Haller H; Strüber M; Welte T; Gottlieb J
    Nephrol Dial Transplant; 2011 Sep; 26(9):3032-8. PubMed ID: 21310739
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Everolimus: a proliferation signal inhibitor with clinical applications in organ transplantation, oncology, and cardiology.
    Gabardi S; Baroletti SA
    Pharmacotherapy; 2010 Oct; 30(10):1044-56. PubMed ID: 20874042
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.